REG - CVS Group plc - Non-Executive Director Appointment

CVSAnnouncement

21/04/2026 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU3465Ba&default-theme=true

RNS Number : 3465B  CVS Group plc  21 April 2026

For Immediate Release
 
 
              21 April 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Non-Executive Director Appointment

 

CVS, the UK listed veterinary group and a leading provider of veterinary
services, is pleased to announce the appointment of Laura Hagan as an
Independent Non-Executive Director with effect from 1 May 2026.

 

Laura is presently an Independent Non-Executive Director and Chair of the
Remuneration Committee at FeverTree Drinks plc and was, until March 2026,
Chief People Officer at Deliveroo plc. Laura's earlier executive roles include
Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc
and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people
leadership, organisation design optimisation, international expansion and the
delivery of customer driven service through technology.  Laura's blend of
experience operating in both FTSE 250 and fast growth privately owned
companies will add value to the board.

 

From the date of her appointment, Laura will become a member of the Group's
Remuneration Committee, Audit and Risk Committee and Nomination Committee.

 

Commenting on the appointment of Laura, CVS Chair David Wilton said:

 

"On behalf of the board, I am delighted to welcome Laura to CVS and I look
forward to working with her. Laura's appointment, following that of Helen
Keays and Jane Bednall announced on 25 March 2026, adds complementary skills
and experience to the Board through her extensive listed company experience
and her expertise in people development, leadership, customer service and
international expansion."

 

The Company confirms that there is no further information about Laura Hagan
requiring disclosure under paragraphs 6.4.8R (1) to (6) of the FCA
UK Listing Rules.

 

 

Contacts

CVS Group plc
                                                via
Camarco

Richard Fairman, Chief Executive Officer

Scott Morrison, Group Legal Counsel and Company Secretary

 

Camarco (Financial
PR)

Ginny Pulbrook
 
  cvsg@camarco.co.uk (mailto:cvsg@camarco.co.uk)

Tilly Butcher
 
+44 (0)20 3757 4980 (tel:+442037574980)

Letaba Rimell
 

 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk) )

CVS Group is a leading provider of veterinary services, operating in the UK
and Australia, listed on the Main Market of the London Stock Exchange.  CVS
is focused on providing high-quality clinical services to its clients and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and
3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUCCCUPQGGG



            Copyright 2019 Regulatory News Service, all rights reserved